Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice
British Journal of Clinical Pharmacology · 2025-04 · 91 (4) · 1064-1079
DOI: 10.1111/bcp.16335 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 21.11.2024. Verfasst von Monika Berezowska und 9 weiteren Autor:innen. Beteiligte Einrichtung: Vesynta Ltd, Innovation Gateway, The London Cancer Hub, Cotswold Road, Sutton, London, UK. Hauptthemen laut MEDLINE: Precision Medicine, Models, Biological, Pharmacokinetics. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UKRI, UK Research and Innovation.
Abstract (Originalsprache)
Current methods of dose determination have contributed to suboptimal and inequitable health outcomes in underrepresented patient populations. The persistent demand to individualise patient treatment, alongside increasing technological feasibility, is leading to a growing adoption of model‐informed precision dosing (MIPD) at point of care. Population pharmacokinetic (popPK) modelling is a technique that supports treatment personalisation by characterising drug exposure in diverse patient groups. This publication addresses this important shift in clinical approach, by collating and summarising recommendations from literature. It seeks to provide standardised guidelines on best practices for the development of popPK models and their use in MIPD software tools, ensuring the safeguarding and optimisation of patient outcomes. Moreover, it consolidates guidance from key regulatory and advisory bodies on MIPD software deployment, as well as technical requirements for electronic health record integration. It also considers the future application and clinical impact of machine learning algorithms in popPK and MIPD. Ultimately, this publication aims to facilitate the incorporation of high‐quality precision‐dosing solutions into standard clinical workflows, thereby enhancing the effectiveness of individualised dose selection at point of care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vesynta Ltd, Innovation Gateway, The London Cancer Hub, Cotswold Road, Sutton, London, UK.
- Translational and Clinical Research Institute, Newcastle University Centre for Cancer, Newcastle upon Tyne, UK.
- Division of Pharmacy & Optometry, School of Health Sciences, University of Manchester, Manchester, UK.
ORCID-Profile: Kayode Ogungbenro, Gareth J Veal, Jugal Suthar
Förderung
- UKRI
- UK Research and Innovation
Zitieren
APA
Berezowska, M., Hayden, I. S., Brandon, A. M., Zats, A., Patel, M., Barnett, S., Ogungbenro, K., Veal, G. J., Taylor, A., & Suthar, J. (2025). Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice. British Journal of Clinical Pharmacology, 91(4), 1064-1079. https://doi.org/10.1111/bcp.16335
Vancouver
Berezowska M, Hayden IS, Brandon AM, Zats A, Patel M, Barnett S, et al. Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice. British Journal of Clinical Pharmacology. 2025;91(4):1064-1079. doi:10.1111/bcp.16335
BibTeX
@article{Berezowska2025,
author = {Berezowska, Monika and Hayden, Isaac S and Brandon, Andrew M and Zats, Arsenii and Patel, Mehzabin and Barnett, Shelby and Ogungbenro, Kayode and Veal, Gareth J and Taylor, Alaric and Suthar, Jugal},
title = {Recommended approaches for integration of population pharmacokinetic modelling with precision dosing in clinical practice},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
volume = {91},
number = {4},
pages = {1064--1079},
doi = {10.1111/bcp.16335}
}
EUVIMED